Literature DB >> 18838971

A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.

Jacqueline de Graaf1, Patrick Couture, Allan Sniderman.   

Abstract

Given the high prevalence of the atherogenic forms of apolipoprotein B (apoB) dyslipoproteinemias and the effectiveness of appropriate therapy, we feel that access for all physicians to simple, effective diagnostic aids that enable use of widely available technology is vitally important in clinical lipidology. In this Review, therefore, we present a diagnostic algorithm for the diagnosis of these disorders that is based on concentrations of total cholesterol, triglyceride and apoB. By including apoB values, lipoprotein number and composition can be deduced and each of the classic dyslipoproteinemias identified. All three parameters can be accurately and inexpensively determined in clinical laboratories and, therefore, this algorithm can be used by any physician to make an accurate diagnosis without use of specialist research laboratories. Just as the application of LDL cholesterol measurement moved clinical practice forward from plasma lipids to lipoprotein lipids, we believe that the use of apoB will further advance diagnosis and treatment of dyslipoproteinemias.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838971     DOI: 10.1038/ncpendmet0982

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  11 in total

Review 1.  The evolution and refinement of traditional risk factors for cardiovascular disease.

Authors:  Emil M deGoma; Joshua W Knowles; Fabio Angeli; Matthew J Budoff; Daniel J Rader
Journal:  Cardiol Rev       Date:  2012 May-Jun       Impact factor: 2.644

Review 2.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

Review 3.  ApoB versus non-HDL-C: what to do when they disagree.

Authors:  Allan Sniderman; Ken Williams; Christa Cobbaert
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

4.  Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.

Authors:  R P Surendran; M E Visser; S Heemelaar; J Wang; J Peter; J C Defesche; J A Kuivenhoven; M Hosseini; M Péterfy; J J P Kastelein; C T Johansen; R A Hegele; E S G Stroes; G M Dallinga-Thie
Journal:  J Intern Med       Date:  2012-02-13       Impact factor: 8.989

Review 5.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

6.  Palmar Striated Xanthomas in Clinical Practice.

Authors:  Nathalie Roy; Daniel Gaudet; Diane Brisson
Journal:  J Endocr Soc       Date:  2022-07-02

Review 7.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

8.  Unfavorable lipoprotein profile in childhood cancer survivors with suprasellar brain tumors--a high Apo B level and increased small dense LDL-cholesterol.

Authors:  Masanori Adachi; Koji Muroya; Yumi Asakura
Journal:  Childs Nerv Syst       Date:  2009-03-05       Impact factor: 1.475

Review 9.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

Review 10.  The Evolving Story of Multifactorial Chylomicronemia Syndrome.

Authors:  Martine Paquette; Sophie Bernard
Journal:  Front Cardiovasc Med       Date:  2022-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.